Venus MedTech, the leading maker of transcatheter aortic heart valve replacement (TAVR) devices in China, has licensed Australia-based Endoluminal Sciences’ active anti-paravalvular leak (PVL) technology, which will be used in Venus’ TAVR products sold in China.
PVL is often called the Achilles’ heel of TAVR. Occurring in the majority of patients undergoing TAVR, its severity is a key factor in the post-procedural mortality of a...